Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), a clinical-stage neuropsychiatry company, has announced its participation in the Water Tower Research Fireside Chat Series on October 8, 2024, at 3:00 p.m. ET. The event will feature Doug Drysdale, Cybin's CEO, in a discussion hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research.
The fireside chat will cover key topics including:
- Cybin's lead development programs CYB003 and CYB004 and upcoming clinical milestones
- Differentiators in Cybin's development approach compared to other neuropsychiatric developments
- Lessons learned and applied from the FDA's Lykos NDA rejection
Interested parties can register for the webcast through a provided link. An archived version of the webcast will be available on Cybin's investor relations website after the event.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), una società di neuropsichiatria in fase clinica, ha annunciato la sua partecipazione alla Water Tower Research Fireside Chat Series il 8 ottobre 2024, alle 15:00 ET. L'evento vedrà la partecipazione di Doug Drysdale, CEO di Cybin, in una discussione condotta da Robert Sassoon, Senior Research Analyst di Water Tower Research.
Il fireside chat affronterà temi chiave tra cui:
- I principali programmi di sviluppo di Cybin CYB003 e CYB004 e i prossimi traguardi clinici
- Le differenze nell'approccio di sviluppo di Cybin rispetto ad altri sviluppi neuropsichiatrici
- Le lezioni apprese e applicate dall'accettazione della domanda NDA di Lykos da parte della FDA
Le parti interessate possono registrarsi per il webcast tramite un link fornito. Una versione archiviata del webcast sarà disponibile sul sito delle relazioni con gli investitori di Cybin dopo l'evento.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), una empresa de neuropsiquiatría en etapa clínica, ha anunciado su participación en la Water Tower Research Fireside Chat Series el 8 de octubre de 2024, a las 3:00 p.m. ET. El evento contará con Doug Drysdale, CEO de Cybin, en una discusión moderada por Robert Sassoon, analista de investigación senior en Water Tower Research.
La charla abordará temas clave, incluyendo:
- Los principales programas de desarrollo de Cybin CYB003 y CYB004 y los próximos hitos clínicos
- Diferenciadores en el enfoque de desarrollo de Cybin en comparación con otros desarrollos neuropsiquiátricos
- Lecciones aprendidas y aplicadas de la rechazo NDA de Lykos por la FDA
Los interesados pueden registrarse para el webcast a través de un enlace proporcionado. Una versión archivada del webcast estará disponible en el sitio web de relaciones con inversionistas de Cybin después del evento.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), 임상 단계의 신경정신의학 회사는 Water Tower Research Fireside Chat Series에 참여한다고 발표했습니다. 2024년 10월 8일 오후 3:00 ET에 진행됩니다. 이 이벤트에서는 Doug Drysdale Cybin의 CEO가 Robert Sassoon Water Tower Research의 선임 연구 분석가의 진행으로 토론을 갖게 됩니다.
이번 파이어사이드 챗에서는 다음과 같은 주요 주제가 다뤄질 예정입니다:
- Cybin의 주요 개발 프로그램인 CYB003 및 CYB004와 향후 임상 이정표
- 다른 신경정신질환 개발과 비교한 Cybin의 개발 접근법의 차별점
- FDA의 Lykos NDA 거부에서 배운 교훈과 적용
관심 있는 분들은 제공된 링크를 통해 웹캐스트에 등록할 수 있습니다. 이벤트 후에 웹캐스트의 아카이브 버전이 Cybin의 투자자 관계 웹사이트에 게재됩니다.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), une entreprise de neuropsychiatrie en phase clinique, a annoncé sa participation à la Water Tower Research Fireside Chat Series le 8 octobre 2024 à 15h00 ET. L'événement mettra en vedette Doug Drysdale, PDG de Cybin, dans une discussion animée par Robert Sassoon, analyste de recherche senior chez Water Tower Research.
La discussion abordera des sujets clés, notamment :
- Les principaux programmes de développement de Cybin CYB003 et CYB004 ainsi que les prochaines étapes cliniques
- Les différences dans l'approche de développement de Cybin par rapport aux autres développements neuropsychiatriques
- Les leçons apprises et appliquées suite au rejet de la NDA de Lykos par la FDA
Les parties intéressées peuvent s'inscrire au webcast via un lien fourni. Une version archivée du webcast sera disponible sur le site web des relations investisseurs de Cybin après l'événement.
Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN), ein Unternehmen für klinische Neuropsychiatrie, hat seine Teilnahme an der Water Tower Research Fireside Chat Series am 8. Oktober 2024 um 15:00 Uhr ET bekannt gegeben. Bei der Veranstaltung wird Doug Drysdale, CEO von Cybin, in einer Diskussion, die von Robert Sassoon, Senior Research Analyst bei Water Tower Research, moderiert wird, teilnehmen.
Das Fireside Chat wird zentrale Themen behandeln, darunter:
- Die führenden Entwicklungsprogramme von Cybin CYB003 und CYB004 und bevorstehende klinische Meilensteine
- Unterscheidungsmerkmale im Entwicklungsansatz von Cybin im Vergleich zu anderen neuropsychiatrischen Entwicklungen
- Erfahrungen und Erkenntnisse aus der Ablehnung des Lykos NDA durch die FDA
Interessierte Parteien können sich über einen bereitgestellten Link für das Webcast registrieren. Eine archivierte Version des Webcasts wird nach der Veranstaltung auf der Investoren-Relations-Website von Cybin verfügbar sein.
- None.
- None.
The fireside chat will be hosted by Robert Sassoon, Senior Research Analyst at Water Tower Research. Covered topics will include:
- Cybin’s lead development programs CYB003 and CYB004 and upcoming clinical milestones.
- What differentiates Cybin’s development approach from other neuropsychiatric developments.
- Lessons learned and applied from the FDA’s Lykos NDA rejection.
To listen to the event, please click here to register for the webcast. The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.
About Cybin
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With industry leading proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin program, about to enter Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated DMT program in a Phase 2 study for generalized anxiety disorder. The company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241003651452/en/
Investor & Media Contact:
Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
irteam@cybin.com – or – media@cybin.com
Source: Cybin Inc.
FAQ
When is Cybin (CYBN) participating in the Water Tower Research Fireside Chat?
What topics will be discussed in Cybin's (CYBN) upcoming fireside chat?
Who will represent Cybin (CYBN) in the Water Tower Research Fireside Chat?
How can investors access Cybin's (CYBN) fireside chat with Water Tower Research?
